| Catalog Number |
CLXSP-I |
| Medical Device Problem Code |
Coagulation in Device or Device Ingredient (1096)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
11/10/2025
|
|
Type of Reportable Event
|
Malfunction
|
|
Additional Manufacturer Narrative
|
|
The system was used for treatment.This case is reportable as a mdr due to the reportable malfunction of the clot observed in the return line.Since this reportable malfunction is only associated with the kit, this mdr will only be against the kit.A batch record review for kit lot n266 was conducted.There were no non-conformances associated with this lot.This lot met all release requirements.A review of kit lot n266 shows no trends.Trends were reviewed for complaint categories, alarm #17: return pressure and clot observed.No trends were detected for these complaint categories.The customer provided photographs for evaluation.The kit was not returned.Review of the photographs confirmed the presence of blood clots in the kit.The blood clots are seen in centrifuge bowl and return lines.Section 5-26 of the cellex operators' manual (b)(4) for use with software 5.7 on anticoagulant states "caution: individual patients may require a heparin dosage that varies from the recommended dose to prevent post-treatment bleeding or clotting during a treatment.The physician should review the patient's medical condition, medications and platelet count at the time of treatment and use clinical judgement to establish the optimal heparin dosage for each patient." the root cause of the alarm #17: return pressure alarm was due to the clots in the kit.The root cause for the clots in the kit could not be determined based on the available information.No further action is required at this time.This investigation is now complete.(b)(4) n.S.(b)(6) 2025.
|
| |
|
Event or Problem Description
|
|
The customer contacted therakos to report blood clotting in the return line with their cellex photopheresis kit ("kit") during an extracorporeal photopheresis (ecp) treatment.The customer reported an alarm #17: return pressure alarm occurred, and they observed blood clots in the return line after 949mls of whole blood was processed.The ecp treatment was aborted and residual blood within the kit was not returned to the patient.The customer reported the patient was in stable condition.The kit return was requested; however, the customer will not return the kit.The customer returned photographs for investigation.
|
| |
|
Additional Manufacturer Narrative
|
|
The smart card data and photographs were returned for evaluation.The complaint kit was not returned for evaluation.A review of the data on the returned smart card confirmed the occurrence of multiple alarm #17: return pressure warnings during a blood prime treatment that was not completed.A visual inspection of the customer provided photographs confirmed the presence of clots in multiple parts of the kit.Section 5-26 of the cellex operators manual (1470619_rev03) for use with software 5.7 on anticoagulant states "caution: individual patients may require a heparin dosage that varies from the recommended dose to prevent post-treatment bleeding or clotting during a treatment.The physician should review the patient's medical condition, medications and platelet count at the time of treatment and use clinical judgement to establish the optimal heparin dosage for each patient." the most likely root cause for the alarm #17: return pressure is due to the clots in the kit.The root cause for the clots in the kit could not be determine based on the available information.No further action is required at this time.(b)(6).
|
| |
|
Search Alerts/Recalls
|